Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Head & Neck 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 43Temozolomide 34Magnetic Resonance Spectroscopy 33Doxorubicin 33Specimen Handling 31Cyclophosphamide 31Vincristine 24Etoposide 21Radiation 20Biopsy 20Ifosfamide 19Filgrastim 18Sirolimus 15Bevacizumab 15temsirolimus 14Sorafenib 13X-Rays 12Surgical Procedures, Operative 12Nivolumab 12Imatinib Mesylate 12Carboplatin 12Radiotherapy, Conformal 11Methotrexate 11Ipilimumab 11Vorinostat 10Peripheral Blood Stem Cell Transplantation 10Irinotecan 10Immunoglobulin G 10Disulfides 10Chemotherapy, Adjuvant 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × bintrafusp alfa protein, human × Sarcoma × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡